Our research systematically explored the correlations of EPHX2 expression with clinical prognosis, clinical characteristics, genetic alterations, immune infiltrations within the tumor microenvironment (TME), tumor mutation burden (TMB), microsatellite instability (MSI), immune modulators, cancer immunotherapy response, and drug sensitivity in 33 cancers, providing valuable insights into potential therapeutic strategies. Here, EPHX2 is linked to neoplasm.